Non-Clinical Overview & Clinical Overview
Ensure Regulatory Confidence by Delivering Comprehensive, High-quality Non-Clinical and Clinical Overviews
CO NCO Services
We offer precise and expert non-clinical and clinical overview services to support your regulatory submissions with precision
Zenovel’s expertise in developing Clinical Overviews (Module 2.5) and Non-Clinical (Module 2.4) ensures that your regulatory filings meet the highest standards and are precise, comprehensive and compliant. Our services, which offer vital information and documentation for a variety of purposes, are intended to assist your drug development process.
- Our Services
- Central Nervous System Depressants
- Anti-Malarial
- Non-steroidal Anti-Inflammatory Drug
- Anti-Hypertensive
- Topical Corticosteroid
- Sedative
- Anti-Emetic
- Anti-Psychotics
- GI - Gastrointestinal Disorders
- Anti-Thyroid
- Immunosuppressants
- Anti-Retroviral
- Pulmonary Fibrosis
- Parkinson Disease
- Anti-Depressants
- Anti-Coagulant
- Anticonvulsants
- Anti-lipedema
Module 2.4 (Non-Clinical Overview Preparation) – Module 2.5 (Clinical Overview Preparation) – Related Literature References (4.3 & 5.4) – Module 1.4.2 (CV & Signature of Non- Clinical Experts) – Module 1.4.3
(CV & Signature of Clinical
Experts)
- Why choose Zenovel CO NCO services?
- Expert Professional
Our team of experienced experts ensures that your overviews are prepared with the highest level of accuracy and detail.
- Regulatory Compliance
We strictly follow all regulatory guidelines, guaranteeing that your submissions are fully compliant and prepared to the highest standards.
- Broad Experience
Our extensive experience in multiple therapeutic areas enables us to handle the complexities with expertise and confidence.
- Quality Commitment
People Also Ask (FAQs)
The Non-Clinical Overview (Module 2.4) summarizes pharmacology, pharmacokinetics, and toxicology data from non-clinical studies. It provides regulators with a scientific interpretation of preclinical findings and their relevance to human clinical trials.
The Clinical Overview (Module 2.5) integrates clinical efficacy and safety data from trials. It explains the benefit-risk profile of the drug and supports regulatory approval decisions.
Zenovel provides expert regulatory and scientific writing services to develop comprehensive Non-Clinical Overview (NCO) and Clinical Overview (CO) documents. These are aligned with global regulatory standards, including FDA, EMA, and ICH CTD guidelines, ensuring clarity, scientific accuracy, and strong regulatory acceptance.
Non-Clinical Overview (NCO) and Clinical Overview (CO) documents are required as part of CTD Module 2 during major regulatory submissions. These documents are typically included when companies submit applications such as IND, NDA, ANDA, or MAA to regulatory authorities. They provide regulators with a high-level scientific interpretation of non-clinical and clinical data, helping evaluate the safety, efficacy, and overall benefit–risk profile of the drug. Zenovel supports the preparation of these documents with expert scientific writing and regulatory expertise, ensuring they are accurate, well-structured, and aligned with global submission requirements.
Professional regulatory writing ensures that complex scientific and clinical data are clearly summarized, interpreted, and aligned with ICH CTD guidelines. Expert writers help maintain consistency across different submission modules, highlight the most relevant findings, and present the benefit-risk assessment effectively. This structured and compliant documentation improves the quality of submissions, minimizes regulatory queries, and increases the likelihood of a smoother review and approval process.
Blogs and news
Our Latest Article
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
